RBC maintains Genaera at sector perform

RBC Capital Markets analyst Michael J. Yee kept Genaera Corp. at a sector perform rating, speculative risk with a reduced price target of $1.50, down from $3. While the analyst believes that Evizon is an active agent in age-related macular degeneration, it will be challenging to demonstrate efficacy and commercialize the product in light of Lucentis. Shares of the Plymouth Meeting, Pa.-based biopharmaceutical company were down $0.0012, or 0.25%, at $0.4788 on volume of 366,097 shares versus the three-month running average of 602,545 shares. (Nasdaq: GENR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.